Q32 Bio (QTTB) corrects director grant to 10,826 stock options
Rhea-AI Filing Summary
Q32 Bio Inc. director Isaac Manke received a grant of stock options for 10,826 shares of common stock on June 12, 2026 at an exercise price of $12.64 per share, expiring on 2036-06-11. This amendment corrects the option amount previously reported. The options vest in full on the earlier of June 12, 2027 or the issuer’s next annual meeting of stockholders, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Manke Isaac
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1, F2 | 10,826 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 10,826 shares (Direct)
Footnotes (2)
- F1. This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
- F2. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Key Figures
Stock options granted: 10,826 shares
Exercise price: $12.64 per share
Expiration date: 2036-06-11
+2 more
5 metrics
Stock options granted
10,826 shares
Stock Option (Right to Buy) granted to director Isaac Manke on 2026-06-12
Exercise price
$12.64 per share
Conversion or exercise price of the options granted on 2026-06-12
Expiration date
2036-06-11
Option expiration date for the June 12, 2026 stock option grant
Vesting date
June 12, 2027
Options vest in full on June 12, 2027 or earlier upon next annual meeting
Post-transaction derivative holdings
10,826 options
Total derivative securities held by Isaac Manke after the reported grant
Key Terms
Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy) reported for the grant"
exercise price financial
"conversion_or_exercise_price of 12.6400 is the option's exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares underlying this option shall vest and become exercisable in full"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders financial
"earlier of June 12, 2027 or the date of the Issuer's next annual meeting of stockholders"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Q32 Bio Inc. (QTTB) report in this Form 4/A?
Q32 Bio reported that director Isaac Manke received a grant of 10,826 stock options for common stock on June 12, 2026, with an exercise price of $12.64 per share and an expiration date of 2036-06-11.
Why was this Form 4/A amendment filed for Q32 Bio (QTTB)?
The Form 4/A was filed to correct the number of options previously reported as awarded to Isaac Manke on June 12, 2026. The footnote states the amendment adjusts the option amount disclosed in the original Form 4 filed on June 16, 2026.
What are the vesting terms of Isaac Manke’s QTTB stock options?
The options will vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, provided Isaac Manke continues his service with the company through the applicable vesting date.
When do Isaac Manke’s Q32 Bio (QTTB) stock options expire?
The reported stock options held by Isaac Manke expire on 2036-06-11. They were granted on June 12, 2026 with an exercise price of $12.64 per share and will be exercisable after the vesting conditions described in the filing are satisfied.
How many QTTB options does Isaac Manke hold after this reported grant?
After the reported transaction, Isaac Manke holds 10,826 stock options related to this grant. The filing lists 10,826 derivative securities following the transaction, each representing the right to acquire one share of Q32 Bio common stock upon exercise.